AJJ MEDTECH HOLDINGS LIMITED

(Company Registration No. 198403368H) (Incorporated in the Republic of Singapore)

RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON 29 APRIL 2024

The board of directors (the "**Board**" or "**Directors**") of AJJ Medtech Holdings Limited (the "**Company**") is pleased to announce that at the extraordinary general meeting of the Company (the "**EGM**") held on 29 April 2024, all the resolutions as set out in the Notice of EGM dated 12 April 2024 were duly approved and passed by shareholders of the Company on a poll vote.

All capitalised terms used in this announcement shall, unless otherwise defined herein, have the respective meanings ascribed to them in the circular dated 12 April 2024 issued by the Company to Shareholders.

The information as required under Rule 704(15) of the Catalist Rules is set out below:

(a) Breakdown of all valid votes cast at the EGM

Resolution number and details	Total number of shares represented by votes for and against the relevant resolution	For		Against	
		No. of shares	As a percentage of total number of votes for and against the resolution (%)	No. of shares	As a percentage of total number of votes for and against the resolution (%)
Ordinary Resolution 1: The Proposed Adoption of the Share Buyback Mandate	530,346,585	530,346,585	100	0	0
Ordinary Resolution 2: The Proposed Diversification	530,346,585	530,346,585	100	0	0

(b) <u>Details of parties who are required to abstain from voting on any resolutions, including</u> the number of shares held and the individual resolution(s) on which they are required to abstain from voting

No party was required to abstain from voting on the resolutions at the EGM.

(c) <u>Name and firm and/or person appointed as scrutineer</u>

Entrust Advisory Pte. Ltd. was appointed by the Company as scrutineer for the conduct of the poll at the EGM.

BY ORDER OF THE BOARD

Zhao Xin Chief Executive Officer and Executive Director 29 April 2024

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited ("**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("**SGX-ST**").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Jerry Chua (Telephone Number +65 6241 6626 at Evolve Capital Advisory Private Limited, 138 Robinson Road, Oxley Tower, #13-02, Singapore 068906.